Chinese medical device makers expand into Europe amid domestic anti-corruption probes
Chinese medical device companies are shifting their focus to Europe as sales plummet from a government anti-corruption campaign affecting hospitals. In the first five months of 2026, purchases by state-supported hospitals in China fell by around 12% compared to last year, largely due to a new anti-corruption probe, according to Linda Shu from HSBC in a July 10 report. This drop has hit the revenues of top Chinese manufacturers hard. One company, Jenscare Scientific from Ningbo, Zhejiang, is making strides in Europe. On July 8, they announced that their LuX-Valve Plus received CE certification, the second device of its kind approved globally, allowing it to be marketed across the EU as a less invasive tricuspid valve replacement.
Key facts
- Government-backed hospital purchases of medical devices in China fell about 12% year-on-year in the first five months of 2026.
- The decline is partly due to a new anti-corruption probe into hospitals.
- Linda Shu, head of China healthcare research at HSBC, reported this in a July 10 report.
- Jenscare Scientific, based in Ningbo, Zhejiang, filed with the Hong Kong stock exchange on July 8.
- Jenscare's LuX-Valve Plus received CE certification under the EU's updated Medical Device Regulation.
- The LuX-Valve Plus is the second device of its kind worldwide to win approval.
- The device replaces a damaged tricuspid valve via a vein, avoiding open-chest surgery.
- Jenscare called the approval a 'milestone' in its international strategy.
Entities
Institutions
- HSBC
- Jenscare Scientific
- Hong Kong stock exchange
- European Union
Locations
- China
- Europe
- Ningbo
- Zhejiang
- Hong Kong